Temsirolimus

Cat. No. 5264

Temsirolimus C56H87NO16 [162635-04-3]

Price and Availability

For Temsirolimus pricing & availability please select your country from the drop down menu:
Submit
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Alternative Name: CCI-779

Chemical Name: Rapamycin 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]

Biological Activity

mTOR inhibitor; inhibits tumor growth in breast cancer cell lines (IC50 values are 1.6 and 4.3 nM for SKBr3 and BT474, respectively). Inhibits HIF-1α-mediated VEGF production in breast cancer cell lines (BT474 and MDA-MB-231). Directly inhibits serum and VEGF mediated endothelial cell proliferation and morphogenesis in vitro and vessel formation in vivo. Causes G1/S cell cycle arrest in multiple cancer cell lines. Antiangiogenic.

Licensing Information

Sold for research purposes under agreement from Pfizer Inc.

Technical Data

M.Wt:
1030.29
Formula:
C56H87NO16
Solubility:
Soluble to 100 mM in DMSO and to 100 mM in ethanol
Purity:
>98 %
Storage:
Store at -20°C
CAS No:
162635-04-3

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.

Certificate of Analysis / Product Datasheet / Safety Datasheet

Li et al (2013) The novel mTOR inhibitor CCI-779 (temsirolimus) induces antiproliferative effects through inhibition of mTOR in Bel-7402 liver cancer cells. Cancer Cell Int. 13. PMID: 23537100.

Wang et al (2012) Inhibition of mammalian target of rapamycin signaling by CCI-779 (temsirolimus) induces growth inhibition and cell cycle arrest in Cashmere goat fetal fibroblasts (Capra hircus). DNA Cell Biol. 31 1095. PMID: 22320865.

Del Bufalo et al (2006) Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 66 5549. PMID: 16740688.

Wu L et al (2005) Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res. 65 2825. PMID: 15805283.

If you know of a relevant reference for this product please let us know.

Citations are publications that use Tocris products.

Do you know of a great paper that uses Temsirolimus from Tocris? If so please let us know.

View Related Products by Product Action

Keywords: Temsirolimus, supplier, Breast, cancer, mTOR, inhibitors, inhibits, rapamycin, kinases, suppresses, cell, tumour, tumor, growth, VEGF, Vascular, endothelial, growth, factor, CCI-779, Tocris Bioscience, mTOR Inhibitor products

Quick Order

Find multiple products by catalog number

divider line

Cancer Research Product Guide

Cancer Research Product Guide

Our Cancer Research Guide highlights over 750 products for cancer research. Request copy or view PDF today.

divider line

Kinase Inhibitor Toolbox

80 Kinase inhibitors
pre-dissolved in DMSO

Kinase Inhibitor Toolbox

Includes many of the latest kinase inhibitors to become commercially available. Covers a wide range of kinase targets including EGFR, MAPK and CDK.

divider line

Kinases Product Listing

Kinases Product Listing

Our Kinase listing highlights over 400 products for kinase research. Request copy or view PDF today.

divider line

Pain Research Product Guide

Pain Research Product Guide

Our Pain guide highlights over 280 products for Pain research. Request copy or view PDF today.

divider line

mTOR Pathway

mTOR Signaling Pathway

The mTOR complexes (mTORC1 and 2) respond to intra- and extracellular signals to mediate cell growth, proliferation and survival. View pathway or download PDF today.

divider line

New Products in this Area

TDZD 8

Selective non-ATP competitive inhibitor of GSK 3β

BI 605906

Selective IKKβ inhibitor

GSK 319347A

Potent and selective IKKε inhibitor

FRAX 597

Potent group I PAK inhibitor

MRT 68921 dihydrochloride

Potent ULK inhibitor; inhibits autophagy

AM 2394

Potent glucokinase activator; orally bioavailable

eCF 309

Potent mTOR inhibitor

PF 3758309 dihydrochloride

Potent PAK4 inhibitor; orally available

AZ Dyrk1B 33

Potent and selective Dyrk1B kinase inhibitor

PF 06409577

Potent and selective allosteric activator of AMPK

Perifosine

PKB/Akt inhibitor; also modulates Kv2.1 current

RAF 265

Raf kinase and VEGFR-2 inhibitor

CZC 25146

Potent LRRK2 inhibitor

Ro 3280

Potent and selective PLK1 inhibitor

RMM 46

MSK/RSK family kinase inhibitor

LTURM 34

Potent DNA-PK inhibitor

MLi-2

Potent and selective LRRK2 inhibitor

LTURM 36

PI 3-kinase δ inhibitor

PI 3065

Potent and selective PI 3-kinase p110δ inhibitor

AZ PFKFB3 67

Potent and selective PFKFB3 inhibitor

STOCK2S 26016

Lysine deficient protein kinase (WNK) signaling inhibitor

Sign-up for new product e-alerts
divider line

Bio-Techne Events

AACR 2017

AACR Annual Meeting 2017

April 1 - 5, 2017

Washington, D.C., USA

Booth: 1239